Loading...
XSHE
300119
Market cap1.15bUSD
Oct 09, Last price  
16.81CNY
1D
1.14%
1Q
7.96%
Jan 2017
-2.21%
IPO
22.22%
Name

Tianjin Ringpu Bio-Technology Co Ltd

Chart & performance

D1W1MN
XSHE:300119 chart
P/E
19.51
P/S
2.30
EPS
0.86
Div yield, %
1.81%
Shrs. gr., 5y
2.46%
Rev. gr., 5y
11.11%
Revenues
3.40b
+10.70%
224,133,644285,355,542345,619,033587,713,347656,393,897754,904,371585,196,982792,834,472969,858,4921,047,334,4881,189,866,0121,466,580,5032,000,407,1062,007,138,3042,007,138,3032,084,250,3992,084,250,3982,709,104,7593,069,933,1163,398,458,452
Net income
401m
+33.18%
43,321,87561,500,93182,539,811114,094,687144,079,000151,958,90626,993,856110,310,758132,782,491104,895,239118,978,858194,359,939398,196,544412,784,534412,784,538346,698,684346,698,687453,593,657300,722,273400,513,483
CFO
298m
-59.55%
19,145,45868,072,29564,590,619112,815,21190,285,52289,918,33188,684,156128,370,937225,265,709207,668,427107,573,523174,881,770383,608,950388,439,470382,628,909389,486,980378,196,328735,546,207297,533,618
Dividend
May 13, 20260.4 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1998 and based in Tianjin, China, Tianjin Ringpu Bio-Technology Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of a broad spectrum of animal health solutions. Their product portfolio includes veterinary biologicals, pharmaceutical formulations, functional feed additives, and active pharmaceutical ingredients (APIs) for the Chinese market. The company provides a wide array of vaccines and medications for livestock, particularly poultry and swine. They also offer a comprehensive line of pet care products, such as inactivated rabies vaccines, recombinant canine-alpha interferon, inhalation anesthetics like isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate injections for bacterial infections, and cardiac treatments including napril chewable tablets. For waterfowl, their specialized offerings include live and inactivated duck tempusu vaccines, purified egg yolk antibodies for gosling plague and duck viral hepatitis, duck infectious serositis inactivated vaccines, as well as injectable and soluble powder treatments like florfenicol and kanamycin. Furthermore, Ringpu develops antifungal products featuring natural plant extracts, immune polysaccharides, probiotics (such as Clostridium butyricum and Lactobacillus plantarum), antibacterial peptides, enzyme preparations, and acidulants. Their disinfection and cleaning range comprises potassium hydrogen persulfate composite powder, various quaternary ammonium compounds (e.g., benzyl trimethyl ammonium chloride, deca methyl ammonium bromide), sodium dichloroisocyanurate, and iodine glycerin solutions. The company's API production includes crucial ingredients like tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, and gamimycin.

Key people

Qiuyue Tong
Deputy General Manager · since 2022
Gang Xie
Secretary of the Board · since 2022
Shoujun Li
Chairman of the Board · since 2023
Rui Li
Director · since 2022
Ailing Liu
Deputy General Manager, Director · since 2019
Guozhu Liu
Staff Elected Director · since 2025
Lei Xu
General Manager, Director · since 2023
Xiutong Zhu
Deputy General Manager, Director · since 2022
Ya Li
Independent Director · since 2025
Chuang Ma
Independent Director
IPO date
Sep 17, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT